REGISTER
Why Has This Chinese Company Secured a "Distant Lead" in the Medical Artificial Intelligence Sector?
The development of Shukun Science and Technology relies on embracing new technologies and seizing the opportunity of medical reform.

If we sort out the leading enterprises in the field of medical subdivision in China, Shukun Science and Technology is definitely one of them.


According to the China Health Statistics Yearbook (2022), there are more than 30000 large-scale hospitals in China, and the digital doctor products of Shukun Science and Technology Co., Ltd. (Hereinafter referred to as "Shukun Science and Technology") have been used in more than 3000 medical and health institutions in China, including more than 90% of the top 100 hospitals and 80% of the target public hospitals. Market coverage is the first in the industry.


Digital science and technology can get the certification of China, the United States and Europe, and can be recognized by the majority of hospitals, its heat and recognition is not from the explosion of "GPT" "artificial intelligence" in 2023, but where does it come from?


With curiosity about medical artificial intelligence, intelligent solutions and products, at the end of 2023, the column "Medical Think Tank" and "Machinery" made a special trip to Beijing to visit Mao Xinsheng, founder and chairman of Shukun Science and Technology.


Start a new career with science and technology


"Create another market"


On Mao Xinsheng's resume, I have to mention his experience in IBM (International Business Machines Corporation). After graduating from Peking University in 1997, his main work experience was in IBM, where he served as Chief Technology Officer of IBM China R & D Center, Dean of IBM Innovation Engineering Institute and member of IBM Global Strategy Committee.


"Early deep cultivation in the field of science and technology, professional training, let me see the context of the development of science and technology, let me understand how to use science and technology to solve the biggest problems, which shaped my thinking paradigm." Mao Xinsheng said that the most important thing for him was to create a market, open up a new career with science and technology, and solve the most complex problems.


Over the past 30 years, Mao Xinsheng has been engaged in R & D and management, leading a global R & D team of more than 7000 people at most, and contacting and taking charge of important projects of medical artificial intelligence technology earlier.


In 2017, Mao Xinsheng, then 45 years old, came out to start his own business. At that time, he clearly saw the future trend of digitalization and intellectualization. He hopes to be a great Chinese enterprise in the world. When he saw the vigorous implementation of China's new medical reform: in that year, the country launched a variety of forms of medical consortium construction, which requires more linkage between higher and lower hospitals, and requires hospitals to promote homogenization; the reform of medical insurance payment methods began to pilot, and now the widespread implementation of DRG/DIP began to sprout, requiring hospitals, departments and doctors to accurately control fees; Public hospitals have abolished drug additions in an all-round way, public hospitals have begun to carry out performance appraisal, and hospitals have to promote high-quality development


When Mao Xinsheng saw the rich demand at different levels, large hospitals were trying to reduce costs and increase efficiency. Because of the lack of high-end technology and talents, lower hospitals needed an intelligent medical and health technology platform to help doctors screen diseases, assist diagnosis and make treatment decisions. He devoted himself to this field without hesitation.


The world's first digital human body platform


Despite 40 years of reform and opening up, China has the largest whole industry chain and single market in the world, and even Chinese Internet enterprises can directly face 1.4 billion huge markets and users with one product, but for entrepreneurs, it is still a narrow escape from death.


For Mao Xinsheng, who has had the experience of studying in a private school since childhood, his favorite is the Analects of Confucius, from which he often likes to find answers.


"In a country of a thousand chariots, we should be respectful and trustworthy, thrifty and loving, and make the people timely." Entrepreneurial leaders should have a sense of awe and be cautious in handling affairs. Later, Mao Xinsheng recalled that if the direction was right, the only thing to do was not to toss about, not to do the wrong thing, not to crave for greatness and success.


He said that his "blessed" people, the technical team under his leadership, overcome difficulties, after several years of efforts, brought out a shining product-digital human body platform, which currently includes digital heart, digital brain, digital chest, digital abdomen and many other sub-products.


One of the earliest products of Shukun Technology is a one-stop stroke solution. According to the epidemiological survey of the Chinese Stroke Society, there are more than 14.94 million stroke patients in China, and 3.3 million new strokes occur every year. Stroke treatment is a race against time, and related studies have shown that every 15 minutes saved increases the likelihood of functional independence by 0.91%. A considerable number of patients are distributed at the grass-roots level. In grass-roots hospitals, due to hardware facilities, working years, overall experience and other factors, they often do not have very good diagnosis and treatment capabilities, let alone quality control standardization.


When stroke patients are admitted to hospital, they need CT plain scan, CTA and CTP examination. Each examination will produce 900-1200 thin-layer images. Even professional and experienced doctors need half an hour for image examination and report. Through the solution of Shukun Science and Technology, it can be completed in a few minutes, and help doctors make decisions, so as to gain more time for diagnosis and treatment and rehabilitation opportunities for patients.


The value of the one-stop stroke solution of Shukun Technology lies in: CT plain scan AI can quickly find the bleeding area and make accurate measurement at the pixel level; ASPECT score AI can automatically outline the brain, automatically calculate the mean value of brain CT and give the ASPECT score, and output the structured report with one key; Head and neck CTA AI can automatically process cerebral vessels in a few minutes, directly mark the location of vascular obstruction or ischemia, and analyze the degree of obstruction. CTP AI can assess the degree of brain damage, quantify core infarction and ischemic penumbra, and assess the chance of salvageable brain tissue.


In the process of upward referral, primary hospitals and higher hospitals often delay treatment passively because of the lack of a unified evaluation system, unified standards and unified professional terms. In this process, the sharing of patient information and the interconnection of diagnostic data can be standardized and homogenized through AI.


Taking this as the standard, Shukun has conquered the key areas of cardiovascular and cerebrovascular diseases, liver diseases, tumors, musculoskeletal diseases and so on.


Taking coronary artery CTA-AI as an example, it can complete the image processing of 18 segments of coronary artery in one minute, the intelligent post-processing of coronary artery, the analysis of vascular stenosis and plaque burden, the CAD-RADS structured report, the data can not be discharged, the CT-FFR is fully automated, and the whole process of CTA + CT-FFR is less than three minutes.


"At present, we have done more than 40 scenarios to improve the efficiency of each user by an order of magnitude, so that each patient can detect and detect health risks in time at a lower cost." Mao Xinsheng said.


Fig.1 provided by the interviewee for the use of digital heart


Mao Xinsheng clearly remembered that there was a patient who had done an "artificial intelligence cardiovascular risk assessment project" in a primary hospital. Although the machine was only a 16-row spiral CT, it was also found by the digital human body that the heart and blood vessels had been severely calcified, and AI was diagnosed as a high-risk group of heart disease. Later, when the patient went to a higher hospital for coronary CT, he found that there were three severe stenoses, and finally all of them were stented. "For routine physical examination, how many people are willing to do coronary CT, the cost is high, but also from the peripheral contrast agent, but our solution is to use basic equipment to do large-scale screening, which is to enable primary health care."


Fig.2 The patient sent a thank-you letter to the primary hospital, and the interviewee provided pictures.


Create value that customers can't refuse


After solving the problem of technology, it is to solve the problem of qualification, and finally to face the market. This should be the trilogy of six years before the founding of Shukun Technology.


Because of the excellent product technology, Shukun has won many qualification certificates. At present, it is the only medical AI high-tech enterprise in the world with NMPA (National Medical Products Administration, State Drug Administration) certification in the key areas of heart, brain, chest and abdomen. At present, it has obtained 12 NMPA Class III certificates, 14 NMPA Class II certificates, 4 EU MDR CE certifications and 2 FDA (Food and Drug Administration) certifications.


This is an "honor" for start-ups. Mao Xinsheng's evaluation is very simple: medical behavior is a particularly serious matter. To revere life, you must first have real kungfu. You must get a very strict certification before investing. But it does not mean that you can be complacent after getting these certificates. "It's like a college student getting a diploma, but it has the basis of commercialization.".


In terms of promoting the market, Mao Xinsheng believes that science and technology enterprises should use technological innovation, product innovation and value innovation to create value that customers can not refuse.


At present, there are more than 3000 medical and health products with high viscosity that use Shukun technology daily. It includes many typical cases, such as the CMR-AI multi-center research project jointly launched with Peking Union Medical College Hospital, and the cooperation with the Second Affiliated Hospital of Xinjiang Medical University, a frontier hospital, to improve the treatment time of stroke in sparsely populated areas.


There is also a case of cooperation with an entire region. In May 2023, Wuzhong District of Suzhou cooperated with Shukun Science and Technology to launch a digital human body intelligent health service project. Thirteen hospitals, including tertiary hospitals and primary medical institutions, have fully launched the new technology of cardiovascular risk AI assessment, which makes Wuzhong District the first area in Suzhou to use AI technology to assess coronary calcification.


AI also enables the acquisition of hospital qualifications, such as the Second Affiliated Hospital of Xinjiang Medical University mentioned by the former. Through cooperation with Shukun Science and Technology, the capacity building of stroke centers has been greatly improved with the help of artificial intelligence, and a national leading and mature green channel for stroke has been established. Every year, it attracts a large number of medical staff from all over Xinjiang to study.


The project of "Establishment and Application of CT Intelligent Diagnosis System for Coronary Heart Disease" jointly declared by Shukun Science and Technology and Beijing Friendship Hospital Affiliated to Capital Medical University was successfully selected as the second prize of the Science and Technology Progress Award. The Department of Medical Imaging, the Department of Nuclear Medicine, the Department of Rheumatology and Immunology, and the Department of Cardiovascular Medicine of Beijing Anzhen Hospital, in conjunction with Shukun Science and Technology, based on the intelligent FAI evaluation system of Shukun Science and Technology, were included in Circulation: Set up another high-quality model of the combination of medicine and engineering, and open up a new horizon for the innovation and clinical application of cardiovascular AI technology.


Let patients be good, let hospitals be good, let doctors be good, which has answered why Shukun Science and Technology can maintain its leading position in the industry.


"Race against time" is on the right path


Medical care is a constantly changing industry. According to the statistics of Yilian system, in 2023, more than 200 policies related to the pharmaceutical industry were issued at the national level. Some of these important policies have a significant impact on an industry.


According to the industry review, in the policy of 2023, the medical insurance policy accounted for nearly half of the total, the collection and the adjustment of the new version of the medical insurance catalogue were normalized, and the supervision of the medical insurance fund showed a high-pressure situation. In terms of medical treatment, important policies were issued in the aspects of graded diagnosis and treatment, high-quality development of public hospitals and rational drug use. In medicine, the drug inspection system has been further improved. In particular, "anti-corruption" has become the most lasting and far-reaching medical event in 2023.


Everyone who is engaged in the medical industry has to think and face this. But Mao Xinsheng is calm about these changes. He believes that in the long run, it is inevitable that the supervision of the medical industry tends to be strict, which is the law of any industry. In this process, public hospitals should develop with high quality, reduce costs and increase efficiency, improve management efficiency, and grade diagnosis and treatment should have referral continuity and homogenization. All these need the help of intelligent medical treatment and artificial intelligence.


Now it seems that Shukun Science and Technology is right. At the forum of this year's annual meeting of the Radiological Society of North America (RSNA), the theme was "Leading Through Change", and the important topic was "Embracing Artificial Intelligence". Mao Xinsheng was impressed by a slogan put forward by the participants- "If you don't master AI in this era, you will be eliminated by the times". "We need constant innovation to embrace change," said Matthew A. Mauro, RSNA's president of the year.


For Mao Xinsheng himself, he always has a burden on him, and he himself said that he has a "sense of mission" to "race against time". In the six years since Shukun Technology was founded, Mao Xinsheng has rarely appeared in public. He spends most of his time leading the team. When he travels on business, he is either catching up on sleep or in meetings. His life has been unified with his work, and when he rests, a cup of tea and a book are both relaxing and thinking.


Mao Xinsheng still misses the scene in the Analects of Confucius, where Confucius and his students discussed the story of Xiu Qi Zhi Ping no matter how bad the conditions were. It is also his wish to lead the team in a good academic atmosphere and working environment, combine with top hospitals, industry experts and research institutes, and make a series of top products to help the global medical and health industry develop with high quality, so that people can enjoy the ubiquitous intelligent medical and health services.


About the "Equipment" column:


The character column of the medical think tank "Machinery" is a high-end interview series launched annually by the medical think tank platform, which aims to reflect industrial innovation and industry change in the era from a strategic perspective and standpoint. Through dialogue with 100 leading figures of innovative medical devices, we discussed the opportunities and challenges of the industry, shared the entrepreneurial stories, innovative products and development strategies of enterprises, so as to show the style of enterprises and leading figures to clinical doctors and nurses, hospital managers and medical professionals.




0
0
Loading